Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:56:15.917Z.
Calculation as of: 2026-10-06T19:56:15.917Z.
Quote observation: 2026-10-06T19:55:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 979ff17a100a324a490b4ea8bab969f4c23ca35a684dd985742eca9c7cd70937
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-09-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
PRICE/OCF RATIO AVG TTM
N/A
PRICE/OCF RATIO AVG 3Y
N/A
PRICE/OCF RATIO AVG 5Y
N/A
PRICE/OCF RATIO AVG 10Y
N/A
PRICE/OCF RATIO AVG 15Y
N/A
PRICE/OCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$597.55M
Price/OCF Ratio
3.22
TTM Avg
7.03
3Y Avg
5.98
5Y Avg
6.64
Market Cap
$596.01M
Price/OCF Ratio
192.95
TTM Avg
152.34
3Y Avg
179.51
5Y Avg
672.66
Market Cap
$632.24M
Price/OCF Ratio
18.93
TTM Avg
42.15
3Y Avg
42.15
5Y Avg
29.81
Market Cap
$582.20M
Price/OCF Ratio
78.59
TTM Avg
75.01
3Y Avg
75.01
5Y Avg
75.01
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | $611.00M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $622.66M | N/A | 72.20 | 236.60 | 236.60 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 3.22 | 7.03 | 5.98 | 6.64 |
| SOPHiA GENETICS S.A. (SOPH)vs › | $626.70M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $596.01M | 192.95 | 152.34 | 179.51 | 672.66 |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $632.24M | 18.93 | 42.15 | 42.15 | 29.81 |
| Prime Medicine, Inc. (PRME)vs › | $636.68M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $637.69M | N/A | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $582.20M | 78.59 | 75.01 | 75.01 | 75.01 |
| Fulgent Genetics, Inc. (FLGT)vs › | $582.09M | N/A | 249.71 | 82.21 | 51.58 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/OCF RATIO |
|---|---|
| 2024-09-30 | 2710.16 |
| 2024-09-27 | 2651.59 |
| 2024-09-26 | 2662.24 |
| 2024-09-25 | 2928.47 |
| 2024-09-24 | 3492.86 |
| 2024-09-23 | 4062.58 |
| 2024-09-20 | 4488.54 |
| 2024-09-19 | 4408.67 |
| 2024-09-18 | 4248.94 |
| 2024-09-17 | 4238.29 |
| 2024-09-16 | 4387.38 |
| 2024-09-13 | 4504.51 |
| 2024-09-12 | 4259.59 |
| 2024-09-11 | 4190.37 |
| 2024-09-10 | 4163.75 |
| 2024-09-09 | 4169.07 |
